Mostra risultati da 51 a 100 di 252
successivo >   < precedente 
Titolo Data di pubblicazione Autore(i) Rivista Editore
Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons 2013 FRAU L; MORELLI M; SIMOLA N EXPERIMENTAL NEUROLOGY
Microglial and astroglial activation by 3,4-methylenedioxymethamphetamine (MDMA) in mice depends on S(+) enantiomer and is associated with an increase in body temperature and motility 2013 FRAU L; SIMOLA N; PLUMITALLO A; MORELLI M JOURNAL OF NEUROCHEMISTRY
Caffeine Consumption and Changes in the Function of Dopaminergic Transmission: Evidence of a Hyperdopaminergic State in Rats Subchronically Treated with Caffeine 2012 Simola, N; Pinna, A; Tronci, E; Seeman, P; Morelli, M Nova Science Publishers, Inc.
Alteration in the progression of dopamine neuron degeneration: May caffeine offer new perspective? 2012 MORELLI M; FRAU L; SIMOLA N EXPERIMENTAL NEUROLOGY
A2A receptor antagonism and dyskinesia in Parkinson’s Disease 2012 MORELLI M; BLANDINI F; SIMOLA N; HAUSER RA PARKINSON'S DISEASE
Rehabilitation improves dyskinesias in Parkinsonian patients: A pilot study comparing two different rehabilitative treatments. 2012 FRAZZITTA G; BERTOTTI G; MORELLI M; RIBOLDAZZI G; PELOSIN E; BALBI P; BOVERI N; COMI C; TURLA M; ...LEVA S; FELICETTI G; MAESTRI R NEUROREHABILITATION
Pharmacological characterization of 50-kHz ultrasonic vocalizations in rats: comparison of the effects of different psychoactive drugs and relevance in drug-induced reward 2012 SIMOLA N; FENU S; COSTA G; PINNA A; PLUMITALLO A; MORELLI M NEUROPHARMACOLOGY
Intensive rehabilitation treatment in parkinsonian patients with dyskinesias: a preliminary study with 6-month followup. 2012 FRAZZITTA G; MORELLI M; BERTOTTI G; FELICETTI G; PEZZOLI G; MAESTRI R PARKINSON'S DISEASE
Late-onset Parkinsonism in NFκB/c-Rel-deficient mice 2012 Baiguera, C; Alghisi, M; Pinna, A; Bellucci, A; DE LUCA, Ma; Frau, L; Morelli, M; Ingrassia, R; B...enarese, M; Porrini, V; Pellitteri, M; Bertini, G; Fabene, Pf; Sigala, S; Spillantini, Mg; Liou, Hc; Spano, Pf; Pizzi, M BRAIN
What do you see as the main priorities, Opportunities, and Challenges in Caffeine Research in the Next Five Years? 2011 FERRÉ S; JENSEN M.B; KEMPF K; MARTIN S; KOLB H; TEMPLE J.L; NARDI A. E; O'CONNOR P.J; SIMOLA N; M...ORELLI M; SVIKIS D. S; LARA D. R; HUGHES R.N; KILLGORE W.D.S JOURNAL OF CAFFEINE RESEARCH
Behavioral, neurochemical, and electrophysiological changes in an early spontaneous mouse model of nigrostriatal degeneration 2011 SGADO' P; VIAGGI C; PINNA A; MARRONE C; VAGLINI F; PONTIS S; MERCURI NB; MORELLI M; CORSINI GU NEUROTOXICITY RESEARCH
Anxyiolytic properties of a 2-phenylindolglyoxylamide TSPO ligand: Stimulation of in vitro neurosteroid production affecting GABAA receptor activity 2011 COSTA B; DA POZZO E; CHELLI B; SIMOLA N; MORELLI M; LUISI M; MACCHERONI M; TALIANI S; SIMORINI F;... DA SETTIMO F; MARTINI C PSYCHONEUROENDOCRINOLOGY
Methylxanthines and Drug Dependence: A Focus on Interactions with Substances of Abuse 2011 MORELLI M; SIMOLA N HANDBOOK OF EXPERIMENTAL PHARMACOLOGY Springer
Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease. 2011 FRAU L; BORSINI F; WARDAS J; KHAIRNAR AS; SCHINTU N; MORELLI M. SYNAPSE
Perinatal asphyxia: current status and approaches towards neuroprotective strategies, with focus on sentinel proteins 2011 HERRERA-MARSCHITZ M; MORALES P; LEYTON L; BUSTAMANTE D; KLAWITTER V; ESPINA-MARCHANT P; ALLENDE C...; LISBOA F; CUNICH G; JARA-CAVIERES A; NEIRA T; GUTIERREZ-HERNANDEZ MA; GONZALEZ-LIRA V; SIMOLA N; SCHMITT A; MORELLI M; TASKER RA; GEBICKE-HAERTER PJ NEUROTOXICITY RESEARCH
Birth asphyxia as the major complication in newborns: Moving towards improved individual outcomes by prediction, targeted prevention and tailored medical care 2011 GOLUBNITSCHAJA O; YEGHIAZARYAN K; CEBIOGLU M; MORELLI M; HERRERA-MARSCHITZ M THE EPMA JOURNAL
Farmaci utilizzati nella terapia della Malattia di Parkinson e di altri disturbi motori 2010 CARTA A.R; PINNA A; CORSINI G.U; CARAMELLI A; MORELLI M Idelson-Gnocchi
Caffeine 2010 MORELLI M; SIMOLA N Springer-Verlag
Adenosine signaling in the basal ganglia 2010 Morelli, Micaela; Simola, Nicola; Popoli, Patrizia; Carta, Annarosa Academic Press
Farmaci antiparkinsoniani ed attivi in altri disturbi motori 2010 Carta, Annarosa; Pinna, Annalisa; Corsini, Giovanni Umberto; Caramelli, Andrea; Morelli, Micaela Idelson-Gnocchi
Nicotinamide prevents the long-term effects of perinatal asphyxia on apoptosis, non-spatial working memory and anxiety in rats 2010 Morales P; Simola N; Bustamante D; Lisboa F; FiedlerI J; Gebicke-Haerter PJ; Morelli M; Tasker RA...; Herrera-Marschitz M EXPERIMENTAL BRAIN RESEARCH
Can dietary substances protect against Parkinson's disease? The case of caffeine 2010 Morelli M; Simola N EXPERIMENTAL NEUROLOGY
Biomarkers for prediction and targeted prevention of Alzheimer’s and Parkinson’s diseases: evaluation of drug clinical efficacy 2010 MANDEL S.A; MORELLI M; HALPERIN I; KORCZYN A.D THE EPMA JOURNAL
Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression 2010 Carta AR; Frau L; Pinna A; Morelli M. EXPERIMENTAL NEUROLOGY
Role of Adenosine in the Basal Ganglia 2010 MORELLI M; SIMOLA N; POPOLI P; CARTA AR Elsevier B.V.
A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug 2010 Pinna A; Tronci E; Schintu N; Simola N; Volpini R; Pontis S; Cristalli G; Morelli M NEUROPHARMACOLOGY
Caffeine Enhances Astroglia and Microglia Reactivity Induced by 3,4-Methylenedioxymethamphetamine (‘Ecstasy’) in Mouse Brain 2010 KHAIRNAR A; PLUMITALLO A; FRAU L; SCHINTU N; MORELLI M NEUROTOXICITY RESEARCH
Pathophysiological roles for purines: adenosine, caffeine and urate 2010 Morelli, Micaela; Carta, Annarosa; Kachroo, A; Schwarzschild, Ma PROGRESS IN BRAIN RESEARCH Björklund A, Cenci M.A.
Potential targets for early diagnosis and neuroprotection in asphyxiated newborns 2009 YEGHIAZARYAN K; PEEVA V; MORELLI M; HERRERA-MARSCHITZ M; GOLUBNITSCHAJA O Nova Science Publishers, Inc.
Prediction and targeted prevention of Parkinson's and Alzheimer's diseases 2009 MANDEL S; HALPERIN I; KORCZYN AD; MORELLI M Nova Science Publishers, Inc.
Behavioural correlates of dopaminergic agonists dyskinetic potential in the 6-OHDA lesioned rat 2009 Carta, Annarosa; Frau, Lucia; Pinna, A; Morelli, Micaela Springer
Caffeine consumption and changes in the function of dopaminergic transmission: evidence of a hyperdopaminergic state in rats subchronically treated with caffeine 2009 SIMOLA N; PINNA A; TRONCI E; SEEMAN P; MORELLI M Nova Science Publishers, Inc.
Effect of caffeine on 3,4- methylenedioxymethamphetamine-induced neuroinflammation in mouse brain 2009 Khairnar A; Plumitallo A; Frau L; Morelli M
Effect of caffeine on 3, 4 – methylenedioxymethamphetamine – induced astroglia and microglia activation in mouse brain 2009 Khairnar A; Plumitallo A; Frau L; Morelli M
Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease 2009 CARTA AR; KACHROO A; SCHINTU N; XU K; SCHWARZSCHILD MA; WARDAS J; MORELLI M JOURNAL OF NEUROCHEMISTRY
Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson's disease 2009 FENU S; WARDAS J; MORELLI M BEHAVIOURAL PHARMACOLOGY
Priming of rotational behavior by a dopamine receptor agonist in hemiparkinsonian rats: Movement-dependent induction 2009 SIMOLA N; DI CHIARA G; DANIELS WMU; SCHALLERT T; MORELLI M NEUROSCIENCE
Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease 2009 Kasture, S; Pontis, S; Pinna A; Schintu, N; Spina, L; Longoni, R; Simola, N; Ballero, M; Morelli, M NEUROTOXICITY RESEARCH
Adenosine A2A receptors and Parkinson's disease 2009 MORELLI M; CARTA AR; JENNER P HANDBOOK OF EXPERIMENTAL PHARMACOLOGY
Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer's and Parkinson's diseases 2009 HALPERIN I; MORELLI M; KORCZYN AD; YOUDIM MB; MANDEL SA NEUROTHERAPEUTICS
Adenosine, adenosine A2A antagonists, and Parkinson's disease 2009 JENNER P; MORI A; HAUSER R; MORELLI M; FREDHOLM BB; CHEN JF PARKINSONISM & RELATED DISORDERS
Anxiolytic-like effects of N,N-dialkyl-2-phenylindol-3-ylglyoxylamides by modulation of translocator protein promoting neurosteroid biosynthesis 2008 DA SETTIMO F; SIMORINI F; TALIANI S; LA MOTTA C; MARINI AM; SALERNO S; BELLANDI M; NOVELLINO E; G...RECO G; COSIMELLI B; DA POZZO E; COSTA B; SIMOLA N; MORELLI M; MARTINI C JOURNAL OF MEDICINAL CHEMISTRY
Blockade of globus pallidus adenosine A2A receptors displays antiparkinsonian activity in 6-hydroxydopamine-lesioned rats treated with D1 or D2 dopamine receptor agonists 2008 SIMOLA N; FENU S; BARALDI PG; TABRIZI MA; MORELLI M SYNAPSE
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat 2008 CARTA AR; FRAU L; PINNA A; PONTIS S; SIMOLA N; SCHINTU N; MORELLI M SYNAPSE
Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence 2008 CARTA A; FRAU L; PONTIS S; PINNA A; MORELLI M PARKINSONISM & RELATED DISORDERS
Increase of dopamine D2(High) receptors in the striatum of rats sensitized to caffeine motor effects 2008 SIMOLA N; MORELLI M; SEEMAN P SYNAPSE
Acute perinatal asphyxia impairs non-spatial memory and alters motor coordination in adult male rats 2008 SIMOLA N; BUSTAMANTE D; PINNA A; PONTIS S; MORALES P; MORELLI M; HERRERA-MARSCHITZ M EXPERIMENTAL BRAIN RESEARCH
Adenosine A2A receptor antagonists and Parkinson’s disease: state of the art and future directions 2008 SIMOLA N; MORELLI M; PINNA A CURRENT PHARMACEUTICAL DESIGN
Adenosine A2A receptor antagonist treatment of Parkinson’s disease 2007 PINNA A; SIMOLA N; MORELLI M Transworld Research Network
Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats 2007 TRONCI E; SIMOLA N; BORSINI F; SCHINTU N; FRAU L; CARMINATI P; MORELLI M EUROPEAN JOURNAL OF PHARMACOLOGY

Questionario e social

Condividi su: